张剑杰，孙波，孙勤. 血清穿透素-3与脓毒症患者严重程度的相关性研究[J]. 中国急救医学, 2019, 39(4): 355-359.
Zhang Jian-jie, Sun Bo, Sun Qin. The correlation research between serum pentraxin-3 and the severity of sepsis. Chinese Journal of Critical Care Medicine, 2019, 39(4): 355-359.
［1］Nakstad B. The diagnostic utility of procalcitonin, interleukin-6 and interleukin-8, and hyaluronic acid in the Norwegian consensus definition for early-onset neonatal sepsis(EONS)［J］. Infect Drug Resist, 2018, 11(2): 359-368.
［2］Barzegar E, Nouri M, Mousavi S, et al. Vasopressin in septic shock; Assessment of sepsis biomarkers： a randomized, controlled trial［J］. Indian J Crit Care Med, 2017, 21(9): 578-584.
［3］Bustamante A, García-Berrocoso T, Penalba A, et al. Sepsis biomarkers reprofiling to predict stroke-associated infections［J］. J Neuroimmunol, 2017, 312(13): 19-23.
［4］Jonsson N, Nilsen T, Gille-Johnson P, et al. Calprotectin as an early biomarker of bacterial infections in critically ill patients： an exploratory cohort assessment［J］. Crit Care Resusc, 2017, 19(3): 205-213.
［5］Hu C, Zhou Y, Liu C, et al. Pentraxin-3, procalcitonin and lactate as prognostic markers in patients with sepsis and septic shock［J］. Oncotarget, 2017, 9(4): 5125-5136.
［6］Lee YT, Gong M, Chau A, et al. Pentraxin-3 as a marker of sepsis severity and predictor of mortality outcomes： a systematic review and meta-analysis［J］. J Infect, 2018, 76(1): 1-10.
［7］Jie H, Li Y, Pu X, et al. Pentraxin 3, a Predicator for 28-Day mortality in patients with septic shock［J］. Am J Med Sci, 2017, 353(3): 242-246.
［8］Hamed S, Behnes M, Pauly D, et al. Diagnostic value of pentraxin-3 in patients with sepsis and septic shock in accordance with latestsepsis-3 definitions［J］. BMC Infect Dis, 2017, 17(1): 554.
［9］Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)［J］. JAMA, 2016, 315(8): 801-810.
［10］Liu B, Ai P, Zheng D, et al. Cerebrospinal fluid pentraxin-3 and CD40 ligand in anti-N-menthyl-d-aspartate receptor encephalitis［J］. J Neuroimmunol, 2018, 315(11): 40-44.
［11］Garlanda C, Bottazzi B, Magrini E, et al. PTX3, a humoral pattern recognition molecule, in innate immunity, tissue Repair, and cancer［J］. Physiol Rev, 2018, 98(2): 623-639.
［12］Koh SH, Shin SG, Andrade MJ, et al. Long pentraxin PTX3 mediates acute inflammatory responses against pneumococcal infection［J］. Biochem Biophys Res Commun, 2017, 493(1): 671- 676.
［13］Sharma A, Khan R, Gupta N, et al. Acute phase reactant, pentraxin 3, as a novel marker for the diagnosis of rheumatoid arthritis［J］. Clin Chim Acta, 2018, 480(10): 65-70.
［14］Cunha C, Aversa F, Lacerda JF, et al. Genetic PTX-3 deficiency and aspergillosis in stem-cell transplantation［J］. N Engl J Med, 2014, 370(5): 421-432.
［15］Huttunen R, Hurme M, Aittoniemi J,et al. High plasma level of long pentraxin 3 (PTX3) is associated with fatal disease in bacteremic patients: a prospective cohort study［J］. PLoS One, 2011, 6(3): e17653.
［16］Uusitalo-Seppl, Huttunen R, Aittoniemi J, et al. Pentraxin-3 (PTX3) is associated with severe sepsis and fatal disease in emergency room patients with suspected infection： a prospective cohort study［J］. PLoS One, 2013, 8(1): e53661.
［17］Bastrup-Birk S, Skjoedt MO, Munthe-Fog L, et al. Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome［J］. PLoS One, 2013, 8(9): e73119.
［18］Thulborn SJ, Dilpazir M, Haldar K, et al. Investigating the role of pentraxin-3 as a biomarker for bacterial infection in subjects with COPD［J］. Int J Chron Obstruct Pulmon Dis, 2017, 12(4): 1199-1205.
［19］Herseth JI, Volden V, Bolling AK, et al. Particulate matter-mediated release of long pentraxin-3 (PTX3) and vascular endothelial growth factor (VEGF) in vitro： limited importance of endotoxin and organic content［J］. J Toxicol Environ Health A, 2017, 80(2): 105-119.
